Aries Wealth Management Sells 155 Shares of Stryker Co. (NYSE:SYK)

Aries Wealth Management trimmed its stake in Stryker Co. (NYSE:SYK) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 620 shares of the medical technology company’s stock after selling 155 shares during the period. Aries Wealth Management’s holdings in Stryker were worth $223,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Darwin Wealth Management LLC bought a new stake in Stryker in the third quarter valued at approximately $36,000. Activest Wealth Management acquired a new stake in Stryker during the 4th quarter valued at approximately $36,000. Crews Bank & Trust bought a new position in Stryker during the 4th quarter worth approximately $39,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker in the 3rd quarter worth approximately $42,000. 77.09% of the stock is owned by institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

SYK stock opened at $388.28 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The business has a 50-day simple moving average of $377.19 and a two-hundred day simple moving average of $366.15. The company has a market capitalization of $148.02 billion, a P/E ratio of 50.04, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company earned $3.46 earnings per share. Research analysts expect that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent analyst reports. Royal Bank of Canada increased their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.